CAPTaINs: Capped And Protected Targeted Immunoproteasome N-End Degrons

Brief Description

CAPTaINs provide a novel, selective, and stable method for selective degradation of protein targets.

Full Description

Capped and Protected Targeted Immunoproteasome N-End Degrons (CAPTaINs) represent a cutting-edge technology that provides novel chimeric compounds that selectively degrade target proteins. This platform utilizes an immunoproteasome recognition sequence which acts as a molecular “cage” to prevent premature degradation. Activation occurs specifically in cells expressing the immunoproteasome, enabling precise, disease-specific protein degradation with improved serum stability and prolonged therapeutic effect.

Suggested uses

• Pharmaceutical development for targeted cancer therapies. 
• Treatment of hematological malignancies including lymphoma and leukemia. 
• Biotech research and drug discovery focused on protein degradation mechanisms. 
• Precision medicine approaches for protein-related diseases.

Advantages

• Selective degradation limited to disease-relevant cells expressing immunoproteasome. 
• Improved serum stability resulting in prolonged degradation response. 
• Innovative molecular design with a recognition sequence for controlled “uncaging.” 
• Reduced off-target effects by avoiding degradation in healthy cells. 
• Lower molecular weight compared to PROTACs, improving cell permeability.

Patent Status

Patent Pending